Kuburi Sarah, Di Passa Anne-Marie, Tassone Vanessa K, Mahmood Raesham, Lalovic Aleksandra, Ladha Karim S, Dunlop Katharine, Rizvi Sakina, Demchenko Ilya, Bhat Venkat
Interventional Psychiatry Program, Mental Health and Addictions Service, St. Michael's Hospital, 193 Yonge Street 6-013, M5B 1M8, Toronto, Ontario, Canada.
Institute of Medical Science, Faculty of Medicine, University of Toronto, 1 King's College Circle, Medical Sciences Building, M5S 1A8, Toronto, Ontario, Canada.
Chronic Stress (Thousand Oaks). 2022 Aug 2;6:24705470221115342. doi: 10.1177/24705470221115342. eCollection 2022 Jan-Dec.
Preliminary evidence supports the use of psychedelics for major depressive disorder (MDD). However, less attention has been given to the neural mechanisms behind their effects. We conducted a systematic review examining the neuroimaging correlates of antidepressant response following psychedelic interventions for MDD. Through MEDLINE, Embase, and APA PsycINFO, 187 records were identified and 42 articles were screened. Six published studies and one conference abstract were included. Five ongoing trials were included from subjective outcomesTrials.gov. Our search covered several psychedelics, though included studies were specific to psilocybin, ayahuasca, and lysergic acid diethylamide. Three psilocybin studies noted amygdala activity and functional connectivity (FC) alterations that correlated with treatment response. Two psilocybin studies reported that FC changes in the medial and ventromedial prefrontal cortices correlated with treatment response. Two trials from a single study reported global decreases in brain network modularity which correlated with antidepressant response. One ayahuasca study reported increased activity in the limbic regions following treatment. Preliminary evidence suggests that the default mode and limbic networks may be a target for future research on the neural mechanisms of psychedelics. More data is required to corroborate these initial findings as the evidence summarized in this review is based on four datasets.
初步证据支持使用迷幻剂治疗重度抑郁症(MDD)。然而,人们对其作用背后的神经机制关注较少。我们进行了一项系统综述,研究迷幻剂干预MDD后抗抑郁反应的神经影像学相关性。通过MEDLINE、Embase和美国心理学会心理学文摘数据库,共识别出187条记录,并筛选了42篇文章。纳入了6项已发表的研究和1篇会议摘要。从主观结果Trials.gov纳入了5项正在进行的试验。我们的搜索涵盖了几种迷幻剂,不过纳入的研究主要针对裸盖菇素、死藤水和麦角酸二乙酰胺。三项裸盖菇素研究指出杏仁核活动和功能连接(FC)改变与治疗反应相关。两项裸盖菇素研究报告称,内侧和腹内侧前额叶皮质的FC变化与治疗反应相关。一项研究中的两项试验报告称,脑网络模块化整体下降与抗抑郁反应相关。一项死藤水研究报告称,治疗后边缘区域活动增加。初步证据表明,默认模式和边缘网络可能是未来迷幻剂神经机制研究的目标。由于本综述总结的证据基于四个数据集,需要更多数据来证实这些初步发现。